Who are paracetamol + caffeine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PCM/Oxy2, Ketorolac + Ranibizumab, quadratus without triamcinolone., paracetamol codein, Ultracet®, Ultracet Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paracetamol-caffeine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

paracetamol + caffeine — Competitive Intelligence Brief

paracetamol + caffeine (paracetamol + caffeine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic. Area: Pain management.

phase 3 Analgesic COX enzymes Pain management Small molecule Live · refreshed every 30 min

Target snapshot

paracetamol + caffeine (paracetamol + caffeine) — GlaxoSmithKline. Paracetamol acts as a non-selective inhibitor of COX enzymes, reducing prostaglandin synthesis and thereby decreasing pain and fever, while caffeine acts as a stimulant and analgesic.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
paracetamol + caffeine TARGET	paracetamol + caffeine	GlaxoSmithKline	phase 3	Analgesic	COX enzymes
PCM/Oxy2	PCM/Oxy2	Maastricht University Medical Center	marketed	Opioid analgesic combination	Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
quadratus without triamcinolone.	quadratus without triamcinolone.	Hospital de Braga	marketed	NSAID	COX enzymes
paracetamol codein	paracetamol codein	Diskapi Yildirim Beyazit Education and Research Hospital	marketed	Analgesic combination (paracetamol + opioid)	COX enzymes (paracetamol); mu opioid receptor (codeine)
Ultracet®	Ultracet®	Labopharm Inc.	marketed	Opioid analgesic combination	Mu-opioid receptor; norepinephrine and serotonin transporters; COX enzymes
Ultracet Tablets	Ultracet Tablets	Pfizer	marketed	Opioid analgesic combination	Mu-opioid receptor; norepinephrine and serotonin transporters; COX enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). paracetamol + caffeine — Competitive Intelligence Brief. https://druglandscape.com/ci/paracetamol-caffeine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab